Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment IndicationPRNewsWire • 01/20/21
Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer PatientsPRNewsWire • 01/11/21
Hoth Therapeutics Announces Licensing Agreement and Collaboration with U.S. Army Medical Research and Development Command (USAMRDC) for Treating Multi-Drug Resistant Bacterial Lung InfectionsPRNewsWire • 01/04/21
Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer PatientsPRNewsWire • 12/23/20
Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in HumansPRNewsWire • 12/10/20
Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin DiseasePRNewsWire • 11/03/20
Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and VaccinePRNewsWire • 11/02/20
Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for Development as a Novel Cancer TherapeuticPRNewsWire • 10/20/20
Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2)PRNewsWire • 09/24/20
Hoth Therapeutics Enters into Sponsored Research Agreement for On-the-Go COVID-19 Testing DevicePRNewsWire • 09/21/20
Hoth Therapeutics Announces Participation at Upcoming Investor Conferences in SeptemberPRNewsWire • 08/28/20
Hoth Therapeutic Announces That It Has Submitted its Request to Australia Ethics Board to Begin Clinical Trial of BioLexa for Atopic DermatitisPRNewsWire • 08/13/20
Hoth Therapeutics Executes Licensing Agreement of VNLG-152 for Treatment of Dermatological DiseasesPRNewsWire • 07/31/20
Hoth Therapeutics Announces Sponsored Research Agreement with VCU for Potential COVID-19 TreatmentPRNewsWire • 06/30/20
Hoth Therapeutics' Scientific Advisory Board Member and Inventor of Licensed Novel Peptide COVID-19 Therapeutic, Dr. Michael Peters, Publishes White PaperPRNewsWire • 06/15/20
Hoth Therapeutics Receives Notice of Allowance for U.S. Patent Regarding Methods for Treating Cancer and Dermatology ConditionsPRNewsWire • 06/08/20
Hoth Therapeutics Announces the Appointment of Michael Peters, Ph.D. to Scientific Advisory BoardPRNewsWire • 05/22/20
Emerging Markets Report: Hoth Therapeutics is Working on a Potential Coronavirus Vaccine (COVID-19)GlobeNewsWire • 03/24/20
